Astec LifeSciences Reports Q1 FY27 Results; Achieves EBITDA Breakeven Amid Market Headwinds
Mumbai, 31 July 2026: Astec LifeSciences Limited (Astec) announced its consolidated financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), comparing performance against Q1 FY26. The company reported a total income of ₹84.3 crore, marking an improvement in operational metrics compared to the previous year.The results show a trend toward improved profitability across key indicators, despite a decline in overall revenue. Astec achieved EBITDA breakeven in Q1 FY27, contrasting with an EBITDA loss of ₹10.5 crore in the corresponding period last year. The company also reduced its net loss after tax for the quarter.
Consolidated Financial Performance Highlights (in ₹ crore)
The financial performance metrics reveal a mixed picture, with revenue decline counterbalanced by operational cost management and improved margins in certain segments.| Particulars | Q1 FY27 | Q1 FY26 | % Change |
|---|---|---|---|
| Total Income | 84.3 | 91.6 | -8.0% |
| Earnings before Depreciation, Interest and Tax (EBITDA) | 0.1 | -10.5 | NM |
| Profit/(Loss) before Tax | (18.7) | (33.0) | NM |
| Profit/(Loss) after Tax | (18.7) | (33.0) | NM |
Segment and Operational Overview
The improvement in the consolidated EBITDA figure is attributed to favorable product mix, enhanced capacity utilization at plants, and improved margins within both the Enterprise and Contract Manufacturing segments.Revenue from Enterprise Products saw significant year-on-year growth of 41.6%, reaching ₹51.8 crore in Q1 FY27, up from ₹36.5 crore in Q1 FY26.
In contrast, revenue generated from Contract Manufacturing and New Products stood at ₹31.8 crore in Q1 FY27, down from ₹54.6 crore in Q1 FY26. This decline was largely attributed to the high base recorded in the corresponding quarter of the previous year.
A breakdown of operational revenues by geography is provided below:
| Category | Q1 FY27 (₹ crore) | Q1 FY26 (₹ crore) | % Change |
|---|---|---|---|
| Enterprise Products | 51.8 | 36.5 | 41.6% |
| Contract Manufacturing & New Products | 31.8 | 54.6 | (41.8%) |
By geography, Exports accounted for ₹33.3 crore in Q1 FY27 compared to ₹45.9 crore in Q1 FY26, showing a decline of 27.5%. Domestic sales revenue stood at ₹50.3 crore in Q1 FY27, up from ₹45.2 crore in Q1 FY26, reflecting an increase of 11.3%.
Chairperson's Commentary
Mr. Vishal Sharma, Chairperson of Astec LifeSciences Limited, commented on the performance, noting that the agrochemical sector continues to manage demand supply imbalance which is anticipated to stabilize over the medium term and positively support the industry.The company announced steps to build its business development and growth capability alongside new product introductions. Astec also continues to explore opportunities to drive efficiencies across its operations.
ASTEC Stock Price Movement
Astec LifeSciences Limited shares gained 3.75% on Friday, climbing to close at ₹655.35 and posting an absolute gain of ₹23.50. The stock registered a traded volume of 91,939 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.